ALTASCIENCES
Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes—but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005365/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 09:00:00 CEST | Press release
Thanks to PUBG IP expansion, inZOI’s strong debut, and BGMI’s global growth, quarter-over-quarter sales are up 41.6%, while operating profit is up 112.2% KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also p
Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform29.4.2025 09:00:00 CEST | Press release
Industry veteran Robert J. Dempsey Appointed Chairman of the Board to Guide Strategic Growth in Europe and the U.S. Azalea (A-zuh-lay-ah)Vision, a HealthTech company engineering the future of sight, today announced the first closing of its €15 million Series A funding round, raising €9 million along with the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429247873/en/ Robert Dempsey, Chairman of the Board, Azalea Vision "Strong participation from repeat investors in this Series A milestone reaffirms their trust in our medical device and innovation for the future of intelligent ocular health,” said Enrique Vega, CEO of Azalea Vision. “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in
A Third of Global CIOs Warn of Unrealistic Board Expectations as The World Bets Big on AI, According to Expereo29.4.2025 09:00:00 CEST | Press release
A new survey commissioned by Expereo exposes the true roadblocks to global AI plans - poor infrastructure, resistance from employees, unreasonable demands A third of global technology leaders believe their board has unrealistic expectations or demands on how new technologies like AI will impact business performance. This is according to an IDC InfoBrief*, commissioned by Expereo, which highlights serious roadblocks to global AI implementation, despite AI being considered critical to fulfilling business priorities. The research of 650 technology leaders in global organizations across Europe, the US and APAC reveals that 34% of global technology leaders have been forced to reassess their technology infrastructure because of rising geopolitical risks, as 37% say geopolitical disruptions are currently impacting their organization’s growth strategies. Amid the volatile economic backdrop, it seems most organizations are placing their bets on AI to drive growth. The research shows that 87% of
Cyber Guru Named Winner of the Coveted Global InfoSec Awards during RSA Conference 202529.4.2025 09:00:00 CEST | Press release
Cyber Guru Wins Hot Company in Security Awareness Training in the 13th Annual Global InfoSec Awards at #RSAC 2025 Cyber Guru, the leading cybersecurity awareness training platform, is proud to announce we have won the “Hot Company - Security Awareness Training” award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429950821/en/ Cyber Guru, Global InfoSec Award Winner 2025 “We’re thrilled to receive one of the most prestigious and coveted cybersecurity awards in the world from Cyber Defense Magazine, during their 13th anniversary as one of the world’s leading independent cybersecurity news and information provider. We knew the competition would be tough and with top judges who are leading infosec experts from around the globe, we couldn’t be more pleased,” said Gianni Baroni, CEO and founder of Cyber Guru. Cyber Guru embodies
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner29.4.2025 07:52:00 CEST | Press release
Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom